Equities Analysts Issue Forecasts for XFOR Q3 Earnings

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) – Research analysts at Brookline Capital Management issued their Q3 2025 earnings per share (EPS) estimates for X4 Pharmaceuticals in a report issued on Thursday, May 1st. Brookline Capital Management analyst L. Cann anticipates that the company will post earnings per share of ($2.80) for the quarter. The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.68) per share.

XFOR has been the subject of several other research reports. Cantor Fitzgerald restated an “overweight” rating and issued a $90.00 price target on shares of X4 Pharmaceuticals in a research note on Wednesday, March 26th. HC Wainwright upped their price target on X4 Pharmaceuticals from $1.50 to $7.00 and gave the stock a “buy” rating in a report on Friday, May 2nd.

X4 Pharmaceuticals Price Performance

Shares of XFOR opened at $3.22 on Monday. The company has a market cap of $18.62 million, a P/E ratio of -35.77 and a beta of 0.73. X4 Pharmaceuticals has a fifty-two week low of $3.05 and a fifty-two week high of $34.20. The company has a quick ratio of 4.80, a current ratio of 4.89 and a debt-to-equity ratio of 1.26. The firm’s 50 day moving average price is $7.34 and its 200 day moving average price is $13.00.

X4 Pharmaceuticals (NASDAQ:XFOR) last released its earnings results on Thursday, May 1st. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of ($4.13) by $4.17. The firm had revenue of $28.81 million during the quarter, compared to analyst estimates of $7.03 million.

Institutional Investors Weigh In On X4 Pharmaceuticals

Several institutional investors have recently modified their holdings of the company. Acorn Capital Advisors LLC purchased a new position in X4 Pharmaceuticals in the fourth quarter valued at $5,363,000. JPMorgan Chase & Co. increased its holdings in shares of X4 Pharmaceuticals by 501.0% in the 4th quarter. JPMorgan Chase & Co. now owns 459,653 shares of the company’s stock valued at $337,000 after acquiring an additional 383,177 shares during the last quarter. Jane Street Group LLC raised its position in shares of X4 Pharmaceuticals by 134.9% during the 4th quarter. Jane Street Group LLC now owns 583,483 shares of the company’s stock worth $428,000 after acquiring an additional 335,036 shares in the last quarter. Deutsche Bank AG lifted its stake in X4 Pharmaceuticals by 559.6% during the fourth quarter. Deutsche Bank AG now owns 267,628 shares of the company’s stock worth $195,000 after purchasing an additional 227,051 shares during the last quarter. Finally, Barclays PLC boosted its holdings in X4 Pharmaceuticals by 196.0% in the third quarter. Barclays PLC now owns 277,682 shares of the company’s stock valued at $185,000 after purchasing an additional 183,861 shares in the last quarter. 72.03% of the stock is owned by hedge funds and other institutional investors.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.